Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.

    ... Myelodysplastic syndromes /myeloproliferative neoplasms (MDS/MPN) comprise a spectrum of ...

    Research Article last updated 09/11/2017 - 8:45am.

  2. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis ...

    Research Article last updated 09/13/2017 - 8:58am.

  3. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

    ... (NGS) in 179 patients (median age 73 years) with primary myelodysplastic syndromes (MDS); risk distribution according to the revised ...

    Research Article last updated 09/18/2017 - 11:05am.

  4. The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression

    ... Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem and progenitor ...

    Research Article last updated 09/13/2017 - 8:25am.

  5. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

    ... landscape of the management of patients with higher-risk myelodysplastic syndromes (HR-MDS). HMAs have improved hematopoiesis and quality of ...

    Research Article last updated 09/11/2017 - 9:04am.

  6. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints

    ... BACKGROUND: Myelodysplastic syndromes (MDS) are a group of clonal neoplasms characterized by ...

    Research Article last updated 09/11/2017 - 8:59am.

  7. Vincent Rusak

    ... Links Myelodysplastic Syndromes ...

    "Like You" Patient Story last updated 03/08/2018 - 9:44am.

  8. Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

    ... treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide ; such modifications are ...

    Research Article last updated 11/08/2017 - 9:12am.

  9. Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?

    ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/23/2017 - 11:14am.

  10. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

    ... Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders ...

    Research Article last updated 08/03/2017 - 9:16am.